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Research Paper
Paclitaxel-induced painful neuropathy is
associated with changes in mitochondrial
bioenergetics, glycolysis, and an energy deficit in
dorsal root ganglia neurons
Natalie A. Duggett, Lisa A. Griffiths, Sarah J.L. Flatters*
Abstract
Painful neuropathy is the major dose-limiting side effect of paclitaxel chemotherapy. Mitochondrial dysfunction and adenosine
triphosphate (ATP) deficit have previously been shown in peripheral nerves of paclitaxel-treated rats, but the effects of paclitaxel in
the dorsal root ganglia (DRGs) have not been explored. The aim of this study was to determine the bioenergetic status of DRG
neurons following paclitaxel exposure in vitro and in vivo. Utilising isolated DRG neurons, we measured respiratory function under
basal conditions and at maximal capacity, glycolytic function, and Adenosine diphosphate (ADP)/ATP levels at 3 key behavioural
timepoints; prior to pain onset (day 7), peak pain severity and pain resolution. At day 7, maximal respiration and spare reserve
capacity were significantly decreased in DRG neurons from paclitaxel-treated rats. This was accompanied by decreased basal ATP
levels and unaltered ADP levels. At peak pain severity, respiratory function was unaltered, yet glycolytic function was significantly
increased. Reduced ATP and unaltered ADP levels were also observed at the peak pain timepoint. All these effects in DRG neurons
had dissipated by the pain resolution timepoint. None of these paclitaxel-evoked changes could be replicated from in vitro paclitaxel
exposure to naive DRG neurons, demonstrating the impact of in vivo exposure and the importance of in vivo models. These data
demonstrate the nature of mitochondrial dysfunction evoked by in vivo paclitaxel in the DRG for the first time. Furthermore, we have
identified paclitaxel-evoked changes in the bioenergetics of DRG neurons, which result in a persistent energy deficit that is causal to
the development and maintenance of paclitaxel-induced pain.
Keywords: Chemotherapy-induced neuropathy, Neurotoxicity, Sensory neuron, Mitochondria, Taxol, Dorsal root ganglia
1. Introduction
Paclitaxel is a first-line taxane-derived chemotherapeutic agent
commonly used in the treatment of breast and ovarian cancers.
The clinical use of paclitaxel is impeded by peripheral neuropathy,
which remains the main dose-limiting side effect because of the
current lack of preventative or treatment approaches (reviewed in
Ref. 16). Patients typically report numbness, tingling, spontane-
ous pain, and evoked pain to mechanical and cold stimuli in their
hands and feet.3,5,23 Recent meta-analysis showed that
paclitaxel-induced peripheral neuropathy affected 44% to 98%
of patients.25 Furthermore, neuropathy can persist for months or
years after the paclitaxel treatment ends.5,25,28 Thus, paclitaxel
treatment is a significant cause of sensory abnormalities and
chronic pain substantially affecting quality of life.27
Several rodent models of paclitaxel-induced painful neuropathy
have been developed (reviewed in Ref. 17). We have used a rat
model evoked by low doses of clinically formulated paclitaxel,
which mimics the scenario of multiple nonconsecutive systemic
injections (akin to treatment cycles), evoking mechanical/cold
hypersensitivities, with similar time-courses to those seen in
patients.11,12,15 Previous studies with this model found an
increased frequency of atypical (swollen and vacuolated) mito-
chondria in C-fibres and myelinated axons of the saphenous
(purely sensory) nerve prior to and during paclitaxel-induced pain,
but not at its resolution.12 In addition, decreased complex I and II-
derived respiration and adenosine triphosphate (ATP) levels were
found in an isolated sciatic (sensory and motor) nerve preparation
prior to and during paclitaxel-induced pain.31 Recently, we have
linked paclitaxel-induced mitochondrial dysfunction to oxidative
stress in vivo. We have shown that inhibition of complex III,
a mitochondrial reactive oxygen species (ROS) producing site,
evoked antinociceptive effects on the development and mainte-
nance of paclitaxel-induced pain.15 Furthermore, we found
evidence that paclitaxel induces neuronal-derived mitochondrial
ROS in the saphenous nerve, dorsal root ganglion (DRG), and
spinal cord, which is poorly controlled by endogenous antioxidant
systems.8
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Swollen mitochondria were also observed in the DRG of
paclitaxel-treated rats,2 suggesting paclitaxel affectsmitochondrial
function within the cell bodies of sensory axons as well as at mid-
axon level. Mitochondria are essential to the cell; governing ATP
production, calcium buffering, ROS production, and a number of
key signalling pathways. However, given the multiple functions
of mitochondria, morphological changes cannot define the nature
of mitochondrial dysfunction. In addition, both oxidative
phosphorylation and glycolysis produce ATP. Thus, to fully
understand the bioenergetic status combined analysis of oxidative
phosphorylation, glycolysis and adenine nucleotide content is
required. Therefore, the aim of this study is to determine the
bioenergetic status of DRG neurons following paclitaxel exposure
in vitro and in vivo. Specifically, utilising isolated DRG neurons, we
have measured respiratory function under basal conditions and at
maximal capacity, glycolytic function, and adenosine diphosphate
(ADP) and ATP levels. These data give novel mechanistic insight
into the bioenergetic environment in sensory neuronal cell bodies
prior to, during, and at the resolution of paclitaxel-induced
mechanical hypersensitivity, providing significant understanding
of paclitaxel-induced mitochondrial dysfunction and energy pro-
duction in relation to pain behaviour. Data from these studies were
previously presented in abstract form.7
2. Methods
2.1. Animals
Adult male Sprague-Dawley rats (starting weight 180-220 g; Harlan,
UK) were kept in a climate controlled roomcontaining only rats. Rats
were housed in groups of 3 to 4 in plastic cages with sawdust
bedding and environmental enrichment materials. Bedding/cages
were changed twice a week. Artificial light was provided on a 12-
hour light-dark cycle (lights on at 7 AM) and standard food and water
were freely available. Throughout all studies, rats were routinely
visually checked and weighed to ensure good health. Health status
prior to treatment was normal. All studies were carried out in
accordance with the UK Animals (Scientific Procedures) Act, 1986
and the IASP ethical guidelines.32 Protocols were approved by the
Ethical Review Panel of King’s College London and conducted
under the UK Home Office project licenses 70/6673 & 70/8015.
2.2. Administration of paclitaxel
The clinical formulation of 6 mg/mL Paclitaxel Solution for Infusion
(CP Pharmaceuticals Ltd, UK or Actavis Ltd, UK) was diluted with
0.9% sterile saline (Fresenius Kabi, United Kingdom) to achieve
a 2mg/mL solution. To replicate the clinical formulation of paclitaxel,
a vehicle stock solution was made consisting of equal parts of
cremophor EL (Sigma, Dorset, United Kingdom) and ethanol. In
experiments using paclitaxel solution manufactured by Actavis Ltd,
the vehicle stock solution also contained 2mg/mL sodium citrate as
per this formulation. For vehicle administration; 1 part vehicle stock
solution was diluted with 2 parts 0.9% sterile saline. Rats received
intraperitoneal 2 mg/kg paclitaxel or equivalent volume of vehicle
solution on 4 alternate days (0, 2, 4, and 6). Animals were dosed
according to their weight, ie, 250 g rat received 0.25 mL injection.
Injectionswere performed in themorning, and ratswere immediately
returned to their home cages afterwards.
2.3. Behavioural assessment of mechanical hypersensitivity
As previously described,11,15 rats were habituated to the testing
environment, and mechanical hypersensitivity was assessed by
withdrawal responses to von Frey filaments with bending forces of
4, 8, and 15 g. Three baseline measurements were taken prior to
paclitaxel or vehicle administration andmechanical hypersensitivity
was measured at 1 to 3 week intervals until the paclitaxel-induced
pain syndrome had resolved. Overall, paclitaxel-induced mechan-
ical hypersensitivity has a delayed onset, reaching maximal
hypersensitivity by day 24, remaining at the maximal plateau for
several weeks and eventually resolves from day 170 onwards.
Three critical timepoints of paclitaxel-induced mechanical hyper-
sensitivity were investigated in these studies (Fig. 1): day 7—24
hours after the last injection of paclitaxel, prior to emergence of
mechanical hypersensitivity; day 24 to 44—peak of mechanical
hypersensitivity (von Frey responses recorded as$2.2 fold higher
than baseline responses); day 170 to 218—resolution of mechan-
ical hypersensitivity (return to individual baseline responses
observed on 2 separate occasions). Variability in the timepoint of
harvest at peak pain and resolution of painwas dictated by the pain
behaviour displayed by individual rats. The total number of rats
used at each timepoint was as follows; day 7—16 vehicle, 16
paclitaxel; peak pain—12 vehicle, 12 paclitaxel; resolution of
pain—12 vehicle, 12 paclitaxel. Sample sizes were based on the
number of animals used in a given experiment.
2.4. Isolation of dorsal root ganglion neurons
Rats were overdosed with pentobarbital, and DRGs were dissected
bilaterally starting from L6/L5 proceeding rostrally and placed in
warmed Minimum Essential Media (MEM; Sigma) containing 1%
penicillin/streptomycin (P/S; Invitrogen, Paisley, United Kingdom).
Fourteen DRGs were harvested per animal. Further dissection
removed the ventral root, and partially removed the dura mater and
dorsal root. Dorsal root ganglia were transferred to fresh MEM
containing 1% penicillin/streptomycin and 2.5 mg/mL collagenase
(type IV; Worthington Biochemicals, United Kingdom) and incubated
at 37˚C for 3 hours. Dorsal root ganglia were triturated and trypsin
(0.25mg/mL; Sigma) added for 10 to 20minutes at 37˚C. The single-
cell suspension was then diluted with MEM containing 10% fetal
bovine serum (FBS; Sigma) 1%P/S, and centrifuged at 1000 rpm for
5 minutes. The pellet was resuspended in MEM containing 1% P/S,
10% FBS, and 0.1 mg/mL DNase I (Worthington Biochemicals,
Reading, United Kingdom) and pipetted onto a 15% bovine serum
albumin (BSA), (w/v in MEM; Sigma) cushion and centrifuged for 10
minutes at 1000 rpm. The layer of debris and myelin formed at the
solution interface was discarded before removing BSA cushion and
media to leave a cell pellet. This pellet was resuspended in MEM
containing 1% P/S, 10% FBS, and 0.1% cytosine arabinoside
(Sigma) before plating. The cell suspension was plated directly onto
XF24 Analyzer multi-well plates (for bioenergetic profile analysis);
white 96-well plates (for ADP/ATP analysis); clear 96-well plates and
poly-d-lysine–coatedsize0glasscoverslips (for cell counts). All plates
were incubatedovernight at 37˚C,5%CO2,beforeassessmentof the
bioenergetic profile or ADP/ATP levels, the following day.
2.5. XF24 Extracellular Flux Analyser and standardization
of assays
The bioenergetic profile refers to the measurement of respiration and
glycolysis under basal conditions and at maximal capacity. The XF24
Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA)
enables the simultaneousmeasurement of extracellular flux changes
in oxygen and protons in media immediately surrounding adherent
cells in a multiwell plate format—for more details see Refs. 10,
22—providing readouts in terms of oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR). Four injection ports (A-D) in
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the cartridge, above the multiwell plate containing cells, allow the
bioenergetic responseof cells to different drugsor compoundswhich
specifically modulate mitochondrial function, to be quantified.10,22
Extensive preliminary experiments identified the ideal standard
conditions for these experiments by determining the optimal cell
density, XF24 measurement parameters and concentrations of
compounds which modulate mitochondrial function. Timings of mix-
wait-measure XF24 cycles allowed ample re-oxygenation and pH
equilibration between measurements (see Supplementary Figure 1,
available online at http://links.lww.com/PAIN/A412). Several carbonyl
cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma) titra-
tion experiments (0.05-0.8 mM) were conducted to determine the
highest concentration (0.2 mM) that maximally increased respiration
without causing the proton motive force to collapse (see Supple-
mentary Figure 2, available online at http://links.lww.com/PAIN/
A412). In addition, oligomycin titration experiments (0.5-1.5mM)were
also performed and found no difference in the degree of response
(seeSupplementary Figure 3, available online at http://links.lww.com/
PAIN/A412).
2.6. Normalisation of bioenergetic profiles
After completion of all experiments, DRG cells were fixed in cold
4% PFA for 15 minutes, washed with PBS, and nuclei stained
with DAPI (1:5000 in PBS) at room temperature, in the dark. XF24
multiwell plates were then scanned on an INCell Analyzer 100 (GE
Healthcare Life Sciences, Amersham, United Kingdom). Twenty-
five images (positioned between well standoffs) were taken over
the area from which OCR and ECAR measurements were
recorded. The individual images were then processed in
CellProfiler software, using a freely available DAPI pipeline,
(version 2.1.1; Broad Institute, Cambridge, MA) to count the total
number of cells, to which OCR/ECAR measurements were then
normalised. Nonmitochondrial respiration was subtracted from
basal respiration, ATP turnover, proton leak, and maximal
respiration values (detailed in Ref. 4). As expected, the enzymatic
dissociation of DRG to isolate DRG neurons resulted in the
presence of nonneuronal cells. The contribution of nonneuronal
cells to the bioenergetic profile was therefore investigated.
Because of high adherence of nonneuronal cells to plasticware
compared with neurons, wells were washed repeatedly with
MEM shortly after plating to preferentially remove the majority of
neurons. Oxygen consumption rate/ECAR measurements on
predominantly nonneuronal cells identified nonneuronal cells as
minimal contributors to the bioenergetic profiles observed when
DRG neurons were present (see Supplementary Figure 4, avail-
able online at http://links.lww.com/PAIN/A412). In addition,
samples of DRG cell suspensions from paclitaxel- and vehicle-
treated rats were plated on poly-d-lysine–coated glass cover-
slips, fixed with cold 4% PFA and stained with DAPI and Neu-N.
Cell counts identified the proportion of neuronal and nonneuronal
cells. Dorsal root ganglion cell preparations contained 8% to 12%
neurons. The proportion of neurons did not significantly change
between treatment groups at any of the 3 timepoints.
2.7. Assessment of bioenergetic profiles of dorsal root
ganglion neurons
On the day of the experiment, XF Assay unbuffered media
(Seahorse Bioscience) containing 2 mM GlutaMAX was warmed
to 37˚C, supplemented with 5mMglucose (Sigma), 1mM sodium
pyruvate (Fisher Scientific, Loughborough, United Kingdom), and
pH adjusted to pH 7.4. Cells were washed in this media, and the
multiwell plate was placed into a 37˚C, 0% CO2 incubator for
approximately 45 minutes. Compounds which specifically
modulate mitochondrial function were used to determine the
bioenergetic profile: oligomycin—inhibits ATP synthase; FCCP—
ionophore that uncouples ATP synthesis from electron transport
chain function; rotenone—inhibits complex I; antimycin A—
inhibits complex III (all from Sigma). All compounds were
dissolved in DMSO (dimethyl sulfoxide; Fisher) to 2.5-mM stock
solutions. These stock solutions were diluted with freshly
prepared XF media (described above) and loaded into injection
ports of the cartridge. During experiments, 3 OCR/ECAR
measurements were recorded prior to and following each
addition from injection ports (A-D). Following these additions,
DRG cells were sequentially exposed to compounds in the
following order: (A) 0.4% DMSO—as control for maximal DMSO
concentration of subsequently injected reagents; (B) 0.5 mM or
1 mM oligomycin; (C) 0.2 mM FCCP; (D) 1 mM antimycin A and
1 mM rotenone (Fig. 2A). Six aspects of respiratory function are
assessed because of the effects of these compounds on OCR:
basal respiration; oxygen consumption attributable to with ATP
turnover; proton leak;maximal respiration; spare reserve capacity
(the respiratory ability of the cell to respond to/overcome stress);
and nonmitochondrial respiration (illustrated in Fig. 2B). Extra-
cellular acidification rate measurements were simultaneously
assessed from the same DRG preparations following 0.4%
Figure 1. Time course of paclitaxel-inducedmechanical hypersensitivity. Graphs show themean6 SEM of the number of withdrawal responses to (A) 4 g, (B) 8 g,
and (C) 15 g von Frey filaments at baseline, day 7, peak pain (day 24-44), and pain resolution (day 170-218), following paclitaxel or vehicle administration at days 0,
2, 4, and 6. *P, 0.05, 2-tailed multiple comparison unpaired t tests with Holm-Sidak correction. Baseline & day 7 n5 40 vehicle, n5 40 paclitaxel; peak pain n5
24 vehicle, n 5 24 paclitaxel; resolution n 5 12 vehicle, n 5 12 paclitaxel.
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DMSO and oligomycin additions (Fig. 2C). Two aspects of
glycolytic function were then determined: basal glycolysis and
glycolytic capacity—the tendency of cells to switch to glycolysis
from oxidative phosphorylation (illustrated in Fig. 2D).
Following in vivo behavioural assessment, DRG cells from 1
paclitaxel-treated rat and 1 concurrent vehicle-treated rat were
harvested (as described above) at each timepoint of interest.
Bioenergetic profiles were determined for each animal from 5 to
10 wells of DRG cells. Sample sizes per treatment group: day 7, n
5 6 animals; peak pain (day 24-29), n 5 5 animals; resolution of
pain (day 170-191), n 5 5 animals. Bioenergetic profiles of naive
DRG cells were also determined following in vitro paclitaxel
exposure prior to or during OCR/ECAR measurements to assess
the effect of preexposure and the presence of acute paclitaxel on
oxygen consumption and glycolysis. Naive DRG cells were
exposed for 1 hour to either paclitaxel (10 mMor 10 nM; Sigma, in
XF assaymedia solution containing 1%DMSO—paclitaxel initially
dissolved in DMSO), vehicle (XF assay media containing 1%
DMSO) or XF assaymedia alone at 37˚C, 5%CO2.Cells were then
washed with XF assay media and bioenergetic profiles de-
termined as described above. In separate experiments, OCR/
ECAR measurements were taken for 1 hour after naive isolated
DRGcells were exposed to paclitaxel (10mMor 10 nM in XF assay
media solution containing 1% DMSO), vehicle (XF assay media
containing 1% DMSO), or XF assay media alone following
baseline OCR/ECAR measurements to determine immediate
effects on OCR/ECAR. Cells were then washed with XF assay
media and bioenergetic profiles determined as described above.
In both sets of experiments, the 4 experimental groups—control,
vehicle, 10 mM paclitaxel, 10 nM paclitaxel were run in parallel in
the samemultiwell plates. Bioenergetic profiles of naive DRGcells
following acute paclitaxel exposure were determined from 2 to 3
wells per animal, n5 5 animals. Paclitaxel concentrations used in
these experiments were based on reported plasma concen-
trations in humans following paclitaxel infusion.14
2.8. Assessment of adenosine diphosphate/adenosine
triphosphate levels in dorsal root ganglion neurons
Six wells containing 50-mL aliquots of DRG cell suspensions were
plated in white-walled (for ADP/ATP analysis) and clear 96 well
plates (for cell counts) per animal and kept overnight at 37˚C, 5%
CO2. ADP/ATP Assays (ab65313; Abcam, United Kingdom) were
used per kit instructions. Background luminescence was
measured following the addition of 100 mL of reaction mix (1:9,
ATP monitoring enzyme: nucleotide releasing buffer [NRB]) to
empty wells. Media (MEM) was removed from wells containing
DRG cells and 50 mL of NRB added. Cells were incubated for 2
minutes at RT. 100 mL of reaction mix was then added to wells
containing cells, and the luminescence recorded (ATP level).
Figure 2. Measurement of bioenergetic profiles of isolated dorsal root ganglion (DRG) neurons using the Seahorse XF24 analyzer. (A and B) show the OCR of
isolated DRG neurons from paclitaxel-/vehicle-treated animals at day 7, under basal conditions and at maximal capacity, normalised to cell number. Data are
expressed as mean6 SEM of 7 wells of cells from one paclitaxel- or vehicle-treated rat. Dashed lines indicate injection of media1 DMSO (A; control), oligomycin
(B), FCCP (C), antimycin A and rotenone (D). (B) shows the same graph as (A), with the 6 different parameters of respiratory function shaded. (C and D) show the
ECAR of isolated DRG neurons from paclitaxel-/vehicle-treated animals at peak pain severity, under basal conditions and at maximal capacity, normalised to cell
number. Data are expressed as mean 6 SEM of 8 wells of cells from 1 paclitaxel- or vehicle-treated rat. Dashed lines indicate injection of media 1 DMSO (A;
control), oligomycin (B). (D) shows the same graph as (C), with the 2 parameters of glycolytic function shaded. ATP, adenosine triphosphate; OCR, oxygen
consumption rate; ECAR, extracellular acidification rate.
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Subsequently, 1 mL of ADP-converting enzyme was added,
incubated for 2 minutes, and luminescence recorded again (ADP
level). Adenosine triphosphate standards were measured con-
currently, and concentrations of ATP and ADP in cell replicates
interpolated from a standard curve. Adenosine triphosphate
standards were made from a 1 mg stock of ATP (Sigma)
reconstituted in NRB. Luminescence values were normalised to
cell numbers taken from concurrent clear-walled 96 well plates,
fixed in cold 4% PFA for 15 minutes and nuclei stained with DAPI
(1:5000 in PBS). Plates were scanned on an INCell Analyzer 100,
taking 34 images of the bottom of the wells. Cell counts were then
determined using CellProfiler software. Following in vivo behav-
ioural assessment, DRG cells from 1 paclitaxel-treated rat and 1
concurrent vehicle-treated rat were harvested (as described
above) at each timepoint of interest. Adenosine diphosphate/ATP
levels were measured as described above from 6 to 8 wells per
animal. Sample sizes per treatment group: day 7, n 5 10 to 11
animals; peak pain (day 28-44), n5 7 animals; resolution of pain
(day 182-218), n 5 7 animals. In separate experiments, naive
DRG cells were exposed for 1 hour to either paclitaxel (10 mM or
10 nM; Sigma, in media containing 1% DMSO—paclitaxel initially
dissolved in DMSO), vehicle (media containing 1% DMSO) or
media alone at 37˚C, 5% CO2, to determine the effect of in vitro
paclitaxel on ADP/ATP levels. Adenosine diphosphate/ATP levels
was measured from 5 wells of DRG cells per condition from each
naive animal, n 5 4 animals.
2.9. Statistics
All statistical analyses were conducted using GraphPad Prism 6
or GraphPad InStat 3 for Windows. To assess development of
paclitaxel-induced mechanical hypersensitivity, 2-tailed multiple-
comparison unpaired t tests with Holm-Sidak correction
compared paclitaxel-treated rats to timepoint-matched vehicle-
treated rats. Changes in OCR and ECAR measures between
paclitaxel- and vehicle-treated rats were analysed using 2-tailed
paired t tests. This was to enable direct pairwise comparison
between DRG neurons from each harvest on a given day
(consisting of 1 paclitaxel-treated rat and 1 vehicle-treated rat)
which were then measured in parallel in the same multiwell plate.
Given the observed changes in these measures, 1-tailed
unpaired t tests were then used to compare differences in ADP/
ATP levels of DRG neurons from paclitaxel- and vehicle-treated
rats. Effects of in vitro paclitaxel or vehicle exposure on OCR and
ECARmeasures, and ADP/ATP levels in naive DRGneuronswere
analysed using 1-way ANOVA with Dunnett post hoc analysis
comparing to control group. Statistical significancewas accepted
at P, 0.05. No further distinction has been made when P, 0.01
or P , 0.001 and is denoted on the figures as P , 0.05.
3. Results
We have consistently found that 4 systemic low-dose (2 mg/kg)
injections of paclitaxel administered on days 0, 2, 4, and 6,
evokes mechanical hypersensitivity with a gradual onset.
Paclitaxel-induced mechanical hypersensitivity takes several
weeks to reach its peak, remains elevated for a few months,
and eventually resolves in approximately 6 months following the
first paclitaxel injection. In these studies, we examined isolated
DRG neurons at 3 key timepoints within the time course of
paclitaxel-induced mechanical hypersensitivity; (1) day 7—24
hours after the last injection of paclitaxel, prior to paclitaxel-
induced pain behaviour, (2) day 24 to 44—peak of paclitaxel-
induced pain behaviour and (3) day 170 to 218—resolution of
paclitaxel-induced pain behaviour. Figure 1 shows the combined
behavioural data from several paclitaxel- and vehicle-treated
cohorts, demonstrating the pain phenotype evident before tissue
isolation for these investigations. As typically expected, we
observed a $2.2-fold significant increase in paw withdrawal
responses to von Frey 4, 8, and 15 g stimulation at the peak of
paclitaxel-inducedmechanical hypersensitivity (Fig. 1, *P, 0.05,
2-tailed multiple comparison unpaired t tests with Holm-Sidak
correction, n 5 12-40 animals). In individual cohorts of animals,
we did not observe significant differences in mechanical
hypersensitivity between paclitaxel-treated rats and vehicle-
treated rats at day 7. However, when these data were collated,
small but statistically significant increases in responses to von
Frey 8 and 15 g at day 7 (Fig. 1B, C) were seen in paclitaxel-
treated rats (*P , 0.05, 2-tailed multiple comparison unpaired t
tests with Holm-Sidak correction). It is highly likely that the
statistical significance evident at these timepoints is due to the
high n numbers, n 5 40 at day 7, following data collation from
multiple cohorts rather than a biological effect.
The XF24 Extracellular Flux Analyser used here enables analysis
of mitochondrial function from intact cells without permeabilisation
or isolating mitochondria. We avoided these techniques because
dysfunctional, swollen mitochondria would not survive the
necessary technical processes, and therefore create a bias to
normal mitochondria, which is not representative of the scenario in
vivo. Not all mitochondrial substrates and inhibitors eg, succinate
can permeate the cell membrane, therefore examination of
complex II-mediated respiration in isolated DRG neurons was not
possible. Preliminary experiments identified the ideal standard
experimental conditions for assessing bioenergetic profiles of
DRG neurons (see Supplementary Figures 1-3, available online at
http://links.lww.com/PAIN/A412). Figure 2 illustrates typical
bioenergetic profile of DRG neurons isolated from paclitaxel- and
vehicle-treated rats and subsequent measures of respiratory
function at day 7 (Fig. 2A, B) and glycolytic function at peak pain
(Fig. 2C, D).Wedetermined that nonneuronal cells had a negligible
impact on the bioenergetic profile both in terms of respiratory and
glycolytic function (Supplementary Figure 4, available online at
http://links.lww.com/PAIN/A412).
Figure 3 illustrates the changes in respiratory function of
isolated DRG neurons of paclitaxel-treated rats compared to
vehicle-treated rats, prior to, during, and at the resolution of
paclitaxel-induced pain. There was no significant difference in the
basal respiration or ATP turnover-linked respiration at any
timepoint investigated (Fig. 3A, B). However, there was
a significant reduction in the maximal respiration and spare
reserve capacity of DRG neurons from paclitaxel-treated rats at
day 7 compared to DRGneurons from concurrent vehicle-treated
rats (Fig. 3C, D, *P, 0.05, paired 2-tailed t tests). This indicates
that paclitaxel impairs the ability of mitochondria to increase their
respiratory function under conditions of stress or higher energy
demand. These effects on mitochondrial respiratory function
were not observed at peak pain or pain resolution timepoints.
In conjunction with investigating the oxygen consumption rate
(OCR), extracellular acidification rate (ECAR) was concurrently
measured, relaying information regarding the glycolytic function of
the isolated DRG neurons prior to, during, and at the resolution of
paclitaxel-induced pain. In contrast to the changes in oxygen
consumption observed at day 7, basal glycolysis and glycolytic
capacity remained unchanged at this timepoint (Fig. 4A, B).
However, at the peak pain timepoint, basal glycolysis and glycolytic
capacity were significantly increased in DRG neurons isolated from
paclitaxel-treated rats compared to DRG neurons from concurrent
vehicle-treated rats (Fig. 4A, B, *P, 0.05, paired 2-tailed t tests).
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Examining DRG neurons in XF assay media without glucose
confirmed that higher basal glycolysis was associated with the
peak of paclitaxel-induced pain (paclitaxel 1.52060.098mpH/min
per 1000 cells; vehicle: 1.20760.042mpH/min per 1000 cells,P5
0.005, 2-tailed paired t test). At the resolution of paclitaxel-
induced pain, there was no significant difference between
paclitaxel- and vehicle-treated rats in these glycolytic measures.
The proportion of neurons vs nonneuronal cells in isolated DRG
preparations from paclitaxel- and vehicle-treated rats did not
significantly change at any timepoint investigated. Thus, our
observed changes in paclitaxel-treated rats are not due to
changes in nonneuronal cell function given that their presence did
not vary between groups and they also have a negligible
contribution to the bioenergetic profile (Supplementary Figure 4,
available online at http://links.lww.com/PAIN/A412).
Given that paclitaxel has been previously shown to remain within
theDRGat day 7 following this dosing regimen,30we investigated if
in vitro paclitaxel exposure to naive isolated DRG neurons affected
respiratory or glycolytic function. Bioenergetic profiles of naiveDRG
neuronswere assessed either in the direct presence of paclitaxel or
following prior preexposure to paclitaxel. One-hour exposure to 10
nM or 10 mM paclitaxel had no effect on basal respiration or ATP
turnover-linked respiration (data not shown). In addition, the
presence of paclitaxel (10 nM or 10 mM) had no effect on maximal
respiration, spare reserve capacity, basal glycolysis, or glycolytic
capacity (Fig. 5A, D). Similarly, 1-hour exposure to paclitaxel (10
nM or 10mM) prior to assessment of bioenergetic profiles also had
no effect on basal respiration, ATP turnover-linked respiration,
maximal respiration, spare reserve capacity, basal glycolysis, or
glycolytic capacity (data not shown).
Adenosine triphosphate synthase is the only complex of the
mitochondrial electron transport chain that can work bidirection-
ally to respond to the energy needs of the cell either converting
ADP to ATP or vice versa. Thus, measuring only ATP levels in cells
may not fully demonstrate the nature ofmitochondrial dysfunction
(discussed further in Ref. 4) and energy production status.
Therefore, given our observed changes in mitochondrial and
glycolytic function, we measured ADP and ATP levels of DRG
neurons isolated from paclitaxel and vehicle-treated rats, prior to,
during, and at the resolution of paclitaxel-induced pain behaviour
(Fig. 6). Adenosine triphosphate levels in DRG neurons from
paclitaxel-treated rats were significantly decreased at day 7 and
peak pain timepoints compared to DRG neurons from concurrent
vehicle-treated rats (Fig. 6A, *P, 0.05 1-tailed unpaired t tests).
Similar ATP levels of DRG neurons from paclitaxel- and vehicle-
treated rats were observed at pain resolution. There was no
statistically significant change in ADP levels of DRG neurons from
paclitaxel-treated rats compared to DRG neurons from vehicle-
treated rats at day 7, peak pain or pain resolution timepoints (Fig.
6B). The ratio of ATP:ADP did not significantly alter in DRG
neurons from paclitaxel-treated rats at any of the 3 timepoints
investigated. The effects of in vitro paclitaxel exposure on ADP/
ATP levels in naive DRG neurons were also examined (Fig. 7).
One-hour exposure to paclitaxel (10 nM or 10 mM) or vehicle (1%
Figure 3. Respiratory function of dorsal root ganglion (DRG) neurons in paclitaxel- and vehicle-treated rats during the time course of paclitaxel-induced pain.
Graphs show the mean6 SEM of (A) basal respiration, (B) oxygen consumption associated with ATP turnover-linked respiration, (C) maximal respiration, and (D)
spare reserve capacity of DRG neurons isolated from paclitaxel- and vehicle-treated rats at day 7, peak pain and resolution of pain timepoints, n5 5 to 6 animals,
per treatment group, per timepoint (5-10 replicates from each animal). *P , 0.05 paired 2-tailed t tests.
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DMSO) had no effect on ATP or ADP levels, or in the ratio of ATP:
ADP compared to control neurons (Fig. 7).
4. Discussion
Bioenergetic pathways and mitochondrial electron transport
activity are tightly controlled to enable cell survival with
spontaneous adaptation to maintain cellular homeostasis.
Therefore, any change in the capacity of these pathways can
have significant impact on cellular function. For the first time, we
have examined oxidative phosphorylation, glycolysis, and ADP/
ATP levels to understand how the main energy producing
pathways alter prior to, during, and at the resolution of
paclitaxel-induced pain in DRG neurons.
Figure 4.Glycolytic function of dorsal root ganglion (DRG) neurons in paclitaxel- and vehicle-treated rats during the time course of paclitaxel-induced pain. Graphs
show the mean6 SEM of (A) basal glycolysis and (B) glycolytic capacity of DRG neurons isolated from paclitaxel- and vehicle-treated rats at day 7, peak pain and
resolution of pain timepoints, n 5 5 to 6 animals, per treatment group, per timepoint (5-10 replicates from each animal). *P , 0.05 paired 2-tailed t tests.
Figure 5. Respiratory and glycolytic function of naive dorsal root ganglion (DRG) neurons during in vitro paclitaxel exposure. Graphs show the mean6 SEM of (A)
maximal respiration, (B) spare reserve capacity, (C) basal glycolysis, and (D) glycolytic capacity of naive DRG neurons during exposure to paclitaxel (10 mM or
10 nM), vehicle (1% DMSO), or control (media only).
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At day 7, 24 hours after the last paclitaxel administration and
prior to marked pain behaviour, both maximal respiration and
spare reserve capacity were significantly impaired in DRG
neurons isolated from paclitaxel-treated rats. This suggests that
although basal respiration is unaffected, the ability of DRG
neurons to respond to stress or higher energetic demand is
diminished by paclitaxel. Paclitaxel is still present within the DRG
at day 7 in this rat model.30 However, direct in vitro paclitaxel
exposure either prior to or during assessment of respiratory
function had no significant effect on respiratory function under
basal conditions or at maximal capacity. This suggests that
prolonged in vivo exposure of paclitaxel is required for impairment
of mitochondrial function in DRG neurons. Significantly less ATP
was found in DRG neurons from paclitaxel-treated rats at day 7
compared to concurrent vehicle controls under normal con-
ditions. These effects could not be replicated in naive DRG
neurons following in vitro paclitaxel exposure, further demon-
strating the importance of in vivo modelling. The decrease in ATP
levels was not accompanied by a significant increase in ADP
levels suggesting that ATP synthase functionality is not reversed.
Furthermore, paclitaxel did not affect ATP turnover-linked
respiration suggesting that the machinery and process of ATP
generation is not impaired by paclitaxel directly. Dorsal root
ganglion neurons from paclitaxel-treated rats at day 7 do not
preferentially switch to glycolysis from oxidative phosphorylation,
thus lower ATP levels are not due to a paclitaxel-evoked
enhanced glycolytic function. Therefore, we suggest that the
deficit in ATP levels observed at day 7 could be due to enhanced
release or leak of ATP from DRG neurons.
At the peak of paclitaxel-induced mechanical hypersensitivity,
measures of respiratory function under basal conditions or at
maximal capacity were unaltered in DRG neurons from paclitaxel-
treated rats compared to concurrent vehicle controls, suggesting
a normalisation of mitochondrial function. However, the glycolytic
function of DRG neurons from paclitaxel-treated rats was
significantly increased at peak pain. This was evident in terms of
basal glycolytic function, but also glycolytic capacity ie, an
increased tendency to switch to glycolysis. This preference for
glycolysis occurred despite unlimited substrates for oxidative
respiration. We also observed significantly decreased levels of
ATP in DRG neurons from paclitaxel-treated rats at peak pain
severity. As glycolysis is less efficient than oxidative phosphoryla-
tion at producingATP, reducedATP levels at peak painmaywell be
a result of this paclitaxel-evoked enhancement of glycolytic
function. We did not observe any significant change in respiratory
function, glycolytic function, or ADP/ATP levels at the pain
resolution timepoint. This further indicates that changes in the
bioenergetic status and ATP levels in DRG neurons observed at
day 7 and peak pain timepoints are contributory factors to the
development and maintenance of paclitaxel-induced pain.
Previous experiments measured oxygen consumption and
ATP levels from an ex vivo teased sciatic nerve preparation in the
Figure 6. Levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), and the ratio of ATP:ADP in dorsal root ganglion (DRG) neurons from paclitaxel-
and vehicle-treated rats during the time course of paclitaxel-induced pain. Graphs show the mean 6 SEM of (A) ATP levels and (B) ADP levels of DRG neurons
isolated from paclitaxel- and vehicle-treated rats at day 7, peak pain and resolution of pain timepoints. (C) shows themean6 SEMof the ratio of ATP:ADP from the
same DRG neuronal preparations. n5 7 to 11 animals, per treatment group, per timepoint (6-8 replicates from each animal). *P, 0.05 1-tailed unpaired t tests.
Figure 7. Levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), and the ratio of ATP:ADP in naive dorsal root ganglion (DRG) neurons following in
vitro paclitaxel exposure. Graphs show the mean 6 SEM of the concentration of (A) ATP levels and (B) ADP levels of naive DRG neurons following exposure to
paclitaxel (10 mM or 10 nM), vehicle (1% DMSO), or control (media only). (C) shows the mean6 SEM of the ratio of ATP:ADP from the same naive DRG neuronal
preparations. n 5 4 animals, with 5 replicates from each animal, per condition.
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same paclitaxel rat model used here at day 7 and peak pain
timepoints only.31 Despite different methodological approaches,
comparison between our data using DRG neurons and data with
sciatic nerves31 provides further understanding of causal
mechanisms of paclitaxel-induced painful neuropathy. Prior to
paclitaxel-induced pain, maximal respiration is impaired in both
DRG neurons and sciatic nerves, but basal respiration at both
sites is unaltered. At the peak of paclitaxel-induced pain, basal
respiration is unaffected in both DRG neurons and sciatic nerves,
yet impaired maximal respiration is only seen in sciatic nerves.
The effects of paclitaxel on ATP levels are the same, prior to, and
during paclitaxel-induced pain. Less ATP was present in DRG
neurons in situ, yet deficits in ATP production in sciatic nerves are
only observed during maximally stimulated conditions. Collec-
tively, this could suggest that mitochondrial dysfunction and ATP
deficit in both DRG neurons and peripheral nerves initiates the
development of paclitaxel-induced pain. Additionally, it is
possible that mitochondrial dysfunction continues to be factor
in themaintenance of paclitaxel-induced pain in peripheral nerves
specifically, whereas mitochondrial function recovers in DRG
neurons, yet an energy deficit persists because of the preferential
switch to glycolysis.
A switch to glycolysis may act as a part of a protective
mechanism for DRG neurons exposed to paclitaxel in vivo. The
dosing regimen of paclitaxel utilised in this study does not
increase ATF3 staining in DRG,12 despite observation of swollen,
abnormal mitochondria in the DRG.2 We have also observed
increased ROS levels in IB41 DRG neurons and spinal neurons
prior to pain onset (day 7).8 Several reports link ROS, and reactive
nitrogen species (RNS), to the initiation of apoptosis (reviewed in
Ref. 21); however, this is not evident in this low-dose paclitaxel
model. Neurons extensively metabolise glucose.24 Glucose
metabolism via the pentose-phosphate pathway (PPP) generates
reduced NADPH, which maintains glutathione levels. Maintained
glutathione levels keep cytochromeC in an inactive state and thus
prevent initiation of apoptosis. These pathways have been shown
to inhibit apoptosis in DRG neurons.29 The PPP and glycolysis are
interlinked (reviewed in Ref. 20). This suggests that the increased
basal glycolysis and glycolytic capacity observed here in DRG
neurons from paclitaxel-treated rats at the peak pain timepoint
may be indicative of increased PPP activity and thus glutathione
levels. Considering that the endogenous antioxidant enzymeGPx
utilises glutathione as a substrate (to convert hydrogen peroxide
to water), increased glutathione may account for the increased
GPx activity we observed in DRG from paclitaxel-treated rats at
the peak pain timepoint.8 The enhanced glycolytic function of
DRG neurons from paclitaxel-treated rats observed here at peak
pain could perhaps be an adaptive mechanism to produce
less ROS.
In recent years, ROS and RNS have been shown to be causal
factors in paclitaxel-induced pain through behavioural studies
with pharmacological scavenging agents.6,11,13,18,19 Mitochon-
dria are a substantial source of ROS. Our previous study showed
elevated mitochondrial ROS in DRG and spinal neurons prior to
development of paclitaxel-induced pain.8 The consequences of
this elevated ROS are likely potentiated by a delayed endogenous
antioxidant response.8 Furthermore, we have shown that in-
hibition of complex III, a mitochondrial ROS producing site,
inhibited the development and maintenance of paclitaxel-
induced pain.15 Collectively, these data suggest that ROS/RNS
are significant drivers in the paclitaxel-induced pain syndrome.
Aside from ROS production, mitochondria are also involved
in other critical cellular pathways that could have a substantial
role in chemotherapy-induced pain. Here, we have shown
compromised bioenergetic function and decreased ATP levels
in DRG neurons prior to development of paclitaxel-induced pain.
This suggests that it is unlikely a single chain of events occurs to
evoke pain following chemotherapy. Alternatively, there are
multiple factors connected to mitochondria that may interlink or
occur simultaneously to initiate and potentially maintain
paclitaxel-induced pain. It is to be determined precisely how
paclitaxel-induced mitochondrial dysfunction translates to
behavioural hypersensitivity. Given the importance of ATP to the
maintenance of pump activity which regulates ion exchange, eg,
Na1/K1 ATPase, it is conceivable that ATP deficit could have
consequences on ion exchange in axons potentially driving
aberrant electrical activity. It has been estimated that;50%of the
ATP in neurons is utilised for the maintenance of ion exchange—
discussed in Refs. 1, 9. Another possibility is presynaptic Ca21
clearance mechanisms, as electrical stimulation of capsaicin-
sensitive DRG neurons showed that presynaptic Ca21 clearance
was predominantly dependent upon Ca21-ATPase and
mitochondria.26
In summary, we have examined how the main energy
producing pathways alter prior to, during, and at the resolution
of paclitaxel-induced pain in the cell bodies of sensory neurons. In
vivo paclitaxel acutely evokes deficits in mitochondrial bio-
energetics in DRG neurons, prior to the emergence of pain
behaviour, which is accompanied by decreased ATP levels.
During paclitaxel-induced pain, DRG neurons preferentially
switch to glycolysis potentially explaining the sustained decrease
in ATP levels. These data elucidate the nature of mitochondrial
dysfunction evoked by paclitaxel in vivo and highlight a persistent
energy deficit in DRG neurons. These events are likely important
factors in the development and maintenance of paclitaxel-
induced painful neuropathy. This study provides further evidence
of differential mechanisms occurring at the initiation compared to
the maintenance of paclitaxel-evoked pain syndrome. Identifying
these mechanisms and their temporal importance will aid
a targeted approach to the development of drugs which can
prevent or reverse chemotherapy-induced painful neuropathy.
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Supplementary Figure 1. Oxygen measurements of isolated DRG neurons from paclitaxel/vehicle-
treated animals at day 7 
In each well, 10 sequential oxygen measurements of the media surrounding the plated cells are taken each 
time the fluorophore probe is lowered and the recording microchamber formed. As the cells continue to 
respire during the measurement, oxygen levels decrease. The fluorophore probe then rises and the 
subsequent mixing cycle allows the media to re-oxygenate before another set of 10 sequential oxygen 
measurements. These raw data show that our timings of the mix-wait-measure XF24 cycles are of 
appropriate length. The straight diagonal lines, without plateau or horizontal drift, formed by the 10 
sequential oxygen measurements show that the measurement period is not too long. The first oxygen 
measurement, prior to and following additions from each injection ports (A-D), is at a very similar oxygen 
level, i.e. returns to the same starting point as the previous measurement cycle, showing that the mix-wait 
period is sufficient to allow complete reoxygenation of the media. 
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Supplementary Figure 2. Titration of optimal FCCP concentration for DRG neurons 
A shows oxygen consumption rates of naïve dissociated DRG neurons after sequential addition of FCCP 
from ports A-D, concentrations above dotted lines indicate final concentration of FCCP at cells. B shows a 
more detailed concentration response; with FCCP injected in smaller increments from ports A-D, 
concentrations above dotted lines indicate final concentration of FCCP at cells. A & B show that an FCCP 
concentration above 0.2μM is toxic to DRG neurons (at our plating density) causing damage to the integrity 
of the mitochondrial membrane, as evidenced through decreased oxygen consumption rates.  
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Supplementary Figure 3. Titration of optimal oligomycin concentration for DRG neurons 
Figure shows oxygen consumption rates of naïve dissociated DRG neurons after sequential addition of 
0.5μM oligomycin from ports A-C, leading to exposure to increasing oligomycin concentrations; 0.5μM, 
1.0μM & 1.5μM. 0.2μM FCCP was injected from port D to verify that the neurons are still respiring. 
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Supplementary Figure 4. Neuronal and non-neuronal contributions to oxygen consumption rates in 
isolated DRG cells 
A shows the effect of removing neurons on the bioenergetic profile, graph shows the mean ± SEM of OCR 
measurements per well (n=5). Dashed lines indicate injection of media + DMSO (A; control), oligomycin 
(B), FCCP (C), antimycin A and rotenone (D). B shows the effect of removing neurons on the glycolytic 
profile, graph shows mean ± SEM of ECAR measurements per well (n=5). Dashed lines indicate injection of 
media + DMSO (A; control), oligomycin (B). No washing refers to isolated, naive DRG cells that were plated 
and incubated overnight before the bioenergetic assessment; the method which was followed throughout 
these studies. Wash times refer to the length of time isolated, naive DRG cells were kept at 37°C before 
washing wells with media. These profiles were observed on three separate occasions (n=5 wells per 
condition, per experiment) spread over a number of months. Across three experimental replicates, five 
wells per condition, non-washed wells contained 8.8-10.2% neurons, whilst washed wells contained 0.2-
1.2% neurons. 
